Medicare has introduced a pilot program aimed at increasing access to certain medications. The program focuses on GLP-1 drugs, which are now more accessible to participants.

Details about the program's specifics are limited, but its duration is known. The demonstration period is set to run for approximately a year and a half.

For more information on the pilot program, including its goals and participant eligibility, readers can refer to the original announcement from Medicare, which provides further details on the initiative that began on July 1, 2026, and is scheduled to conclude on December 31, 2027.